Cargando…

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells

The efficacy of chemotherapy for cancer treatment can be increased by targeted drug delivery to the cancer cells. This is particularly important for triple negative breast cancer (TNBC) for which chemotherapy is a major form of treatment. Here we designed and screened a library of 30 peptides starti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hossein-Nejad-Ariani, Hanieh, Althagafi, Emad, Kaur, Kamaljit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389950/ https://www.ncbi.nlm.nih.gov/pubmed/30804365 http://dx.doi.org/10.1038/s41598-019-38574-y

Ejemplares similares

A Small Peptide Increases Drug Delivery in Human Melanoma Cells
por: Tong, Shirley, et al.
Publicado: (2022)

Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer
por: Saghaeidehkordi, Azam, et al.
Publicado: (2021)

Disabling the Nuclear Translocalization of RelA/NF-κB by a Small Molecule Inhibits Triple-Negative Breast Cancer Growth
por: Kanzaki, Hirotaka, et al.
Publicado: (2021)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
por: Inoue, Satoshi, et al.
Publicado: (2012)

Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides
por: Yu, Yung-Luen, et al.
Publicado: (2013)

Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
por: Sebastian, Anusha, et al.
Publicado: (2016)

The development of activatable lytic peptides for targeting triple negative breast cancer
por: Zhao, Hui, et al.
Publicado: (2017)

Peptide density targets and impedes triple negative breast cancer metastasis
por: Liu, Daxing, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
por: Zoeller, Jason J., et al.
Publicado: (2020)

Suppressing Src-Mediated EGFR Signaling by Sustained Calcium Supply Targeting Triple-Negative Breast Cancer
por: Jeong, Keun-Yeong, et al.
Publicado: (2023)

Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer
por: Morgenroth, Agnieszka, et al.
Publicado: (2019)

Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer
por: Sood, Neelam, et al.
Publicado: (2014)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies
por: Korolkova, Olga Y., et al.
Publicado: (2020)

EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
por: Xia, Lin, et al.
Publicado: (2020)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Development of CAPER peptides for the treatment of triple negative breast cancer
por: Chilewski, Shannon D., et al.
Publicado: (2020)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Surface roughness modulates EGFR signaling and stemness of triple-negative breast cancer cells
por: Rosado-Galindo, Heizel, et al.
Publicado: (2023)

Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer
por: Huang, Yongxiu, et al.
Publicado: (2023)

Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
por: Chen, Zhong, et al.
Publicado: (2015)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2011)

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
por: Teng, Yvonne Hui-Fang, et al.
Publicado: (2011)

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
por: Dakroub, Rayan, et al.
Publicado: (2023)

EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Wang, Chao-Qun, et al.
Publicado: (2017)

EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling
por: Song, Xiang, et al.
Publicado: (2020)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Radosevic-Robin, Nina, et al.
Publicado: (2021)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment
por: Zhang, Chaoyu, et al.
Publicado: (2022)

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers
por: Ogden, Angela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sgpnc6furmosvsvldibgmpto1t